Research Article

Colorectal Adenoma Stem-like Cell Populations: Associations with Adenoma Characteristics and Metachronous Colorectal Neoplasia

Angela N. Bartley1, Nila Parikh2, Chiu-Hsieh Hsu3,4, Denise J. Roe3,4, Julie A. Buckmeier3, Lynda Corley1, Ron A. Phipps1, Gary Gallick2, Peter Lance3,5,6, Patricia A. Thompson3,6, and Stanley R. Hamilton1

Abstract

Cancer stem cells have tumor-initiation and tumor-maintenance capabilities. Stem-like cells are present in colorectal adenomas, but their relationship to adenoma pathology and patient characteristics, including metachronous development of an additional adenoma ("recurrence"), has not been studied extensively. We evaluated the expression of aldehyde dehydrogenase isoform 1A1 (ALDH1A1), a putative stem cell marker, in baseline adenomas from the placebo arm of chemoprevention trial participants with colonoscopic follow-up. An exploratory set of 20 baseline adenomas was analyzed by ALDH1A1 immunohistochemistry with morphometry, and a replication set of 89 adenomas from 76 high-risk participants was evaluated by computerized image analysis. ALDH1A1-labeling indices (ALI) were similar across patient characteristics and in advanced and nonadvanced adenomas. There was a trend toward higher ALIs in adenomas occurring in the right than left colon (P = 0.09). ALIs of synchronous adenomas were correlated (intraclass correlation coefficient 0.67). Participants in both sample sets who developed a metachronous adenoma had significantly higher ALIs in their baseline adenoma than participants who remained adenoma free. In the replication set, the adjusted odds for metachronous adenoma increased 1.46 for each 10% increase in ALIs (P = 0.03). A best-fit algorithm–based cutoff point of 22.4% had specificity of 75.0% and positive predictive value of 70.0% for metachronous adenoma development. A larger population of ALDH1A1-expressing cells in an adenoma is associated with a higher risk for metachronous adenoma, independent of adenoma size or histopathology. If confirmed, ALDH1A1 has potential as a novel biomarker in risk assessment and as a potential stem cell target for chemoprevention. Cancer Prev Res; 6(11); 1162–70. © 2013 AACR.

Introduction

Colorectal adenoma is a well-known precursor to colorectal carcinoma, and its removal is associated with a reduced incidence of colorectal cancer (1–6). Among patients who form an adenoma, risk of developing future metachronous colorectal neoplasia in another site in the large bowel, commonly termed “recurrence,” is based on the clinicopathologic features of the patient and the presenting adenoma. Subsequent risk is higher in patients who present with clinical features of three or more adenomas or at least one adenoma that is large (≥1 cm) or has histopathologic features of villous architecture or high-grade dysplasia, termed an advanced adenoma (6–8).

Although colorectal adenomas are relatively common in the general population, with a prevalence of 20% to 30% over age of 50 years, most are small lesions with low-grade dysplasia, of which it is estimated that only approximately 5% to 10% would progress to cancer (6). As a result, yields from endoscopy-based short-interval surveillance for 3 to 5 years are dominated by the detection and removal of small, low-risk adenomas with little discernible clinical significance. These results challenge the cost-effective delivery of endoscopic follow-up and the overall clinical value of screening and surveillance for prevention of colorectal cancer in the average-risk population (9).

Although controversial, cancer cells with stem cell-like properties in solid tumors are thought to comprise a subpopulation with self-renewing and multipotent differentiation properties that are functionally analogous to adult stem cells (10–12). Cancer stem cells are defined functionally by their ability to initiate tumors in xenografts, form spheroids in vitro, have tumor-maintenance capabilities
after chemotherapy, and express various markers in a broad spectrum of organ-specific tumors including colorectal carcinoma (13–21).

Stem-like cells have been reported among premalignant colorectal cells of patients (21–27) and in animal models of colorectal tumorigenesis (28, 29). However, in contrast with the large number of published studies on subpopulations of cells with tumor-initiating properties in cancers, there is a paucity of information about such cells in benign neoplasms such as colorectal adenoma, including their clinicopathologic associations and clinical relevance.

Numerous expression biomarkers for identifying stem cells and cells with stem-like properties have been described previously (10, 11, 13, 30, 31). These include the product of the aldehyde dehydrogenase isoform 1A1 (ALDH1A1) gene, a member of the ALDH superfamily on chromosome 9q21.13 (32–38). This superfamily of proteins catalyzes the irreversible oxidation of a range of endogenous and exogenous intracellular aldehydes to their corresponding carboxylic acids, and metabolizes aldehyde intermediates for synthesis from retinol to retinoic acid, a modulator of cell proliferation. These enzymes also metabolize folate, a micronutrient that is important in various cellular functions in which deficiency has been associated with risk of colorectal tumors (36). The enzymatic activity and expression of ALDH1A1 have been shown to mark subpopulations of colorectal epithelial cells with stem-like properties (10, 13, 20, 23, 39, 40). Mucosal epithelial cells as well as tumor cells isolated from patients with colitis (40) by use of antibody to ALDH1A1 form spheroids and xenografts, representing properties that are characteristic of stem cells. Thus, ALDH1 immunohistochemistry has been used extensively to evaluate stem-like cells in colorectal tumors (10, 13, 20, 23, 39, 40) as well as numerous other tumor types.

In this study, we hypothesized that stem-like cells in colorectal adenoma could be related to clinicopathologic characteristics and the development of metachronous adenoma. We therefore characterized the population of ALDH1A1-expressing cells as an indicator of “stem-cell burden” in baseline adenoma from an exploratory subset and a replication subset of placebo-treated participants with available tissues from two completed chemoprevention trials with protocol-driven follow-up colonoscopy (41, 42).

Materials and Methods

Exploratory and replication study groups

Two sets of specimens were obtained from participants randomized to the placebo arms of the Wheat Bran Fiber Trial (42) or Ursodeoxycholic Acid Trial (41) at the University of Arizona (Tucson, AZ) for the prevention of metachronous colorectal adenomas. Characteristics of these exploratory and replication sample subsets are presented in Table 1. Age, gender, and adenoma clinical characteristics (size and location) were obtained by review of colonoscopy and pathology reports in medical records. Tubular, tubulovillous, or villous architecture and grade of dysplasia in routine histopathologic slides prepared from tissue blocks were determined by central review by gastrointestinal pathologists participating in the conduct of the trials.

For the initial exploratory study sample, we identified 20 baseline tubular adenomas with low-grade dysplasia from a convenience sample of trial participants who had residual banked tissue blocks and known metachronous adenoma status at follow-up colonoscopy. Ten (50.0%) of these subjects with a baseline adenoma in the exploratory set

| Table 1. Baseline characteristics of study participants with baseline adenoma specimens in the exploratory and replication sets |
|-----------------------------|-----------------------------|
|                            | Exploratory set (n = 20 subjects)a | Replication set (n = 76 subjects)b |
| Age (y), mean ± SD          | 66.0 ± 9.7                   | 64.9 ± 9.3                        |
| Male sexc                   | 16 (80.0)                    | 48 (63.2)                         |
| Family history of colorectal cancerc | 4 (20.0)                    | 15 (20.6)                         |
| Current smokerd             | 1 (5.00)                     | 6 (7.89)                          |
| Advanced adenomae           | 12 (60.0)                    | 76 (100)                          |
| Large adenoma (≥1 cm)       | 11 (55.0)                    | 66 (86.8)                         |
| High-grade dysplasia        | 1 (5.00)                     | 10 (13.2)                         |
| Villous histology           | 7 (35.0)                     | 51 (67.1)                         |
| Any proximal adenomae       | 6 (30.0)                     | 34 (47.2)                         |
| Multiple (≥3) adenomasd     | 2 (10.0)                     | 24 (31.6)                         |
| Adenoma at follow-up    c   | 10 (50.0)                    | 40 (52.6)                         |

aIncludes 20 subjects with colorectal adenomas.
bIncludes only participants at high risk of metachronous adenoma on the basis of presentation with ≥3 adenomas and/or an advanced adenoma (≥1.0 cm or with villous histology or high-grade dysplasia).
cNumber and percentage.
had a metachronous adenoma at follow-up. Eleven mucosal biopsy specimens from other trial participants were used as positive controls for ALDH1A1 immunohistochemistry (Fig. 1A and B).

After completion of the analysis of the exploratory subset, 98 additional participants with at least one available inventoried baseline adenoma tissue block and recorded follow-up colonoscopy results were identified from the tissue database of the placebo-control arms of the trials. This second subset of participant samples was designated as the replication set. Immunohistochemistry for ALDH1A1 could not be conducted on 28 of 124 (22.6%) inventoried tissue blocks from 22 participants (22.4%) because of inadequate residual adenoma tissue in their archived specimen. The resulting study set of 89 individual adenomas was derived from 76 subjects who presented with three adenomas and/or histopathologic features of advanced adenoma (i.e., ≥1.0 cm or with villous histology or high-grade dysplasia; refs. 38, 40, 41, 43).

In total, 65 participants (85.5%) in the replication set had one baseline adenoma, and the other 11 (14.5%) had at least two synchronous baseline adenomas, with two of these 11 participants having a third baseline adenoma. These subjects with multiple adenomas permitted within-participant comparisons of adenoma ALDH1A1 levels. In addition, among the 76 subjects, 4 participants had two blocks available from the same adenoma, permitting a limited intraadenoma comparison.

The clinical trial protocols, including retrieval and subsequent laboratory evaluation of specimens obtained at colonoscopy, were reviewed and approved by the University of Arizona Institutional Review Board. The Institutional Review Board at the University of Texas MD Anderson Cancer Center (Houston, TX) approved the laboratory studies protocol.

**Immunohistochemistry for ALDH1A1 expression**

Expression of the stem cell marker ALDH1A1 was evaluated by immunohistochemistry, as reported previously (43). The mouse monoclonal antibody (Catalog #611195; BD Biosciences) identified cells that formed spheroids in vitro and successful xenografts in vivo in a previous study (40).
Manual immunohistochemistry was used for the exploratory set of cases. For evaluation of the larger replication set, the immunohistochemistry procedure was automated on an IntelliPATH FLX slide stainer (Biocare Medical). Reagents, steps, and conditions were identical to those used for the exploratory set.

Morphometric and image analysis of ALDH1A1 expression

Morphometry was used to enumerate ALDH1A1-positive stem-like cells in neoplastic epithelium of the adenomas of the exploratory set and in the crypt columns of control mucosa. Quantitation of ALDH1A1 expression based on predominantly nuclear staining was conducted in coded slides by a gastrointestinal pathologist (A.N. Bartley), without access to information about the participant’s metachronous adenoma status. The topographic distributions of ALDH1A1-expressing epithelial cells in the neoplastic glands of the adenomas and in the control mucosal crypt axes of the immunohistochemistry controls were evaluated by counting cells in four specified regions: surface epithelium and the calculated lower, middle, and upper thirds of the adenoma glands and crypt columns. The total number of cells and the number with nuclear staining were enumerated in 20 microscopic fields at ×40 magnifications in each of the four topographic sites for each slide, and the ALDH1A1-labeling indices (ALI) were calculated as percentage.

For the larger replication set of adenomas, ALIs were quantitated by computerized image analysis with the Aperio ScanScope XT automated image analyzer (Aperio Technologies, Inc.). Aperio Genie Pattern Recognition software was used to identify adenoma glands for evaluation, and the Aperio Genie nuclear v9.1 algorithm was used to create a custom expression classifier. Multiple sampled areas of each adenoma were digitally extracted to create a montage consisting of all acquired representative areas. The same steps were then repeated to identify stroma and other unevaluated tissue areas with histologic defects that interfered with adenoma epithelial image analysis. The montage for each individual adenoma was saved in a custom Genie Training Macro that was tested to assess the accuracy of separating tumor from stroma and unwanted areas in comparison with histopathology. The results were deemed satisfactory when more than 90% mean sensitivity and specificity were obtained to represent the adenoma epithelium and unwanted areas.

Because ALDH1A1 is predominantly expressed in nuclei (44), the Aperio Genie nuclear v9.1 algorithm was used to create a custom ALDH1A1 classifier with color computer graphics (Supplementary Fig. S1). A curvature threshold adjustment was made to decluster groups of closely apposed or overlapping nuclei. The original factory algorithm was also adjusted to increase the upper threshold setting from 230 to 250 to ensure accurate detection of positive and negative regions representative of the light microscopic appearances. The final custom algorithm combined with the training macro was then used on all slides. The results were presented as a separate analysis of the adenoma in each slide with the percentage of positive regions in three levels of expression intensity. Because of the frequent random orientation of adenoma glands and the finding in the exploratory set that differences were apparent in all gland compartments, ALDH1A1-expressing regions across the glands in the entire immunohistochemistry tissue sections were quantitated.

Topographic evaluation of the upper regions of adenoma glands in the replication set was carried out in an exploratory analysis to provide ALIs for the upper third of glands that was included in the evaluation of the exploratory set of adenomas. The oriented areas, when present, of each specimen that included both the surface epithelium and the muscularis mucosae and/or deep lamina propria visible in its whole slide image were demarcated for image analysis of the upper thirds of the glands.

Statistical analysis

Demographic and clinical characteristics of participants and pathologic characteristics of adenomas were analyzed. In the exploratory set, comparison of ALIs across compartments within the same participant was conducted using Wilcoxon signed-rank tests. Comparisons in specimens from participants with and without a subsequent metachronous adenoma were conducted using Wilcoxon rank sum tests. In the replication set, logistic regression with a likelihood ratio test was used to assess the statistical significance of the relationship between ALIs and subsequent adenoma detection at follow-up colonoscopy. Therefore, all participant-level analyses were conducted using both the mean and the maximum ALI value for all adenomas of each participant. We also evaluated the relationship between ALIs and clinicopathologic covariates using logistic regression, including characteristics of the advanced or nonadvanced adenomas at baseline. In addition, we used a classification and regression tree (CART) analysis based on binary recursive partitioning to explore an optimal cutoff point for ALIs to maximize the reduction in impurity and best classify the subject for metachronous adenoma status at follow-up.

Results

Exploratory set: ALDH1A1 expression in baseline adenomas and subsequent metachronous adenoma status

For adenomas in the exploratory set (Fig. 1C–F), ALIs were higher overall (mean 31.7% for deep gland epithelium and 5.0% for surface epithelium) compared with non-neoplastic control mucosa (6.3% for lower crypt epithelium and 1.8% for surface epithelium; P = 0.02). Independent of whether or not the baseline adenoma was advanced, the participants who developed a metachronous adenoma had significantly higher ALIs in their baseline adenoma than participants who did not have an adenoma at follow-up (33.8% vs. 11.9%, P = 0.002, for deep glands; 34.5% vs. 6.7%, P = 0.002, for middle glands; 16.9% vs.
2.4%, \( P = 0.002 \), for upper glands; 8.2% vs. 2.1%, \( P = 0.03 \), for surface epithelium; Fig. 2).

**Replication set: ALDH1A1 expression in baseline adenomas and characteristics of adenomas and participants**

To assess the general reproducibility of the results obtained in the exploratory set, we evaluated ALIs in a second, larger set of specimens that were from a high-risk cohort (i.e., patients presenting with three or more adenomas or an adenoma with advanced features). ALIs were obtained in a final sample size of 89 individual baseline adenomas from 76 participants. ALDH1A1 expression was determined with automated immunohistochemistry and quantitated with computerized image analysis across each adenoma as contrasted with evaluation of topographic glandular regions, due to variability in the orientation of adenomas in the second set of tissue blocks. At the polyp level, 33 of the baseline adenomas were advanced, and 56 were nonadvanced small tubular adenomas.

There were no significant associations between ALIs of the adenomas and participant age or gender (data not shown). We observed a nonsignificantly higher mean ALI among proximal adenomas compared with distal adenomas in the left colon and rectum (22.1% vs. 16.0%; \( P = 0.09 \)). Of note, at the individual adenoma level there were no differences in ALIs between nonadvanced and advanced adenomas (mean ALDH1A1 of 16.3% for nonadvanced vs. 18.5% for advanced; \( P = 0.45 \); Fig. 3). High and low ALIs were found in both advanced and nonadvanced adenomas. The ALIs in the 11 participants with more than one adenoma (i.e., synchronous baseline adenomas) were similar in 9 participants and discordant in 2 (Figs. 3 and 4; Supplementary Fig. S2), with an overall intraclass correlation coefficient of 0.67.

**Replication set: ALDH1A1 expression in baseline adenomas and subsequent metachronous adenoma status**

As was found in the exploratory set using topographic determination of ALIs, subjects who developed an adenoma at follow-up had a significantly higher mean ALI (Fig. 4) than those who did not develop an adenoma at follow-up (22.5% vs. 15.0%; \( P = 0.03 \)). When ALDH1A1 expression was treated as a continuous variable, the OR for metachronous...
For the nonadvanced and advanced adenoma subgroups (group-level data) indicated by the plus (+) signs. The subjects with a significantly higher values: 23.0% as compared with 8.6% for subjects who remained adenoma free (p < 0.05).

Replication set: ALDH1A1 expression in baseline adenomas as a predictor of metachronous adenoma development

In an effort to identify a potentially useful ALI cutoff point that could be used for further investigation as a tissue biomarker for predicting metachronous adenoma risk in high-risk adenoma patients, we conducted a data-driven CART analysis. The splitting algorithm identified an ALI cutoff point of ≥22.4% ALDH1A1-expressing cells as an optimal threshold for classifying risk of metachronous adenoma in our sample (Table 2). The frequency of metachronous adenomas was 75.0% for ALIs above this CART cutoff point and 39.6% for ALIs below the cutoff point (OR, 4.58; 95% CI, 1.63–12.86; p = 0.004). In contrast, the metachronous adenoma rate was 63.6% for ALIs at or above the mean ALI (18.9%) and 44.2% for expression below the mean (OR, 2.21; 95% CI, 0.87–5.60; p = 0.11). Results similar to these with use of the means were obtained for the median ALI values.

We also assessed the sensitivity and specificity of ALI for the development of a metachronous adenoma using a cutoff of 0.5 for the predicted probability. Incorporating ALI increased both the sensitivity and specificity over age, male gender, and advanced status of adenomas, especially when ALDH1A1 expression was treated as a binary variable based on the CART cutoff point of ≥22.4% or <22.4% (Table 3). For the final model with the binary ALI cutoff point for ALDH1A1 expression, sensitivity for development of an adenoma at follow-up among the high-risk cohort was 52.5% with specificity of 75.0%, and positive and negative predictive values of 70.0% and 58.7%, respectively (Table 3).

**Discussion**

We report for the first time that the fraction of ALDH1A1-expressing putative stem-like cells in colorectal adenoma epithelium is correlated among synchronous adenomas in individual patients, and that the presence of a larger subpopulation of these adenoma stem-like cells is associated with increased risk for the patient to have a metachronous adenoma at another location in the large bowel at follow-up. Of note, the association between percentage of ALDH1A1-expressing adenoma cells and risk of a metachronous adenoma is independent of both the adenoma and clinical characteristics previously reported to be associated with increased risk (i.e., villous architecture, high-grade dysplasia, and size of the baseline adenoma, and age and male sex of the study subjects). Our findings raise the possibility that a larger stem-like cell subpopulation in a baseline adenoma may serve as a quantifiable biomarker for the propensity of a patient to develop a subsequent adenoma.

![Image](https://cancerpreventionresearch.aacrjournals.org/2129-6989/6/11/1167/R-P-1167-g004.jpg)

Figure 4. Percentage of ALDH1A1-expressing stem-like cells in 89 baseline adenomas of subjects without and with metachronous adenoma at follow-up colonoscopy (recurrence) in replication set. ALI by automated immunohistochemistry and computerized image analysis is shown for each adenoma (lesion-level data). Multiple adenomas in individual participants are connected by lines and have similar indices in 9 of 11 subjects (intraclass correlation coefficient 0.67). The median ALIs for the nonadvanced and advanced adenoma subgroups (group-level data) are indicated by the plus (+) signs. The subjects with a significantly higher values: 23.0% as compared with 8.6% for subjects who remained adenoma free (p < 0.05).

**Table 2.** ALI and odds of metachronous adenoma in replication set

<table>
<thead>
<tr>
<th>ALI cutoff point (%)</th>
<th>Metachronous rate ≥ cutoff point (%)</th>
<th>Metachronous rate &lt; cutoff point (%)</th>
<th>OR (95% CI)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean 18.9</td>
<td>63.6</td>
<td>44.2</td>
<td>2.21 (0.87–5.60)</td>
<td>0.11</td>
</tr>
<tr>
<td>Median 16.5</td>
<td>63.2</td>
<td>42.1</td>
<td>2.36 (0.94–5.92)</td>
<td>0.11</td>
</tr>
<tr>
<td>CART 22.4</td>
<td>75.0</td>
<td>39.6</td>
<td>4.58 (1.63–12.86)</td>
<td>0.004</td>
</tr>
</tbody>
</table>

*Referent group is metachronous rate less than cutoff point.
colo rectal neoplasm. If corroborated, this biomarker could aid in modifying follow-up recommendations for patients who have an adenoma found and removed.

We confirmed previous reports of approximately 6.0% ALDH1-positive cells in non-neoplastic crypts and approximately 30% in adenomatous glands, representing a five- to six-fold increase in ALDH1 expression with progression to premalignancy (23). We found similar mean ALDH1A1-labeling percentages: 6.3% in non-neoplastic crypts of participants who all had at least one adenoma and 31.7% in adenomatous glands. Although our sample size is small, we found for the first time the presence of highly correlated intraadenoma, intraparticipant ALIs in 4 participants who had at least two blocks from the same adenoma, indicating intratumoral homogeneity within different regions of each tumor. Of even greater interest, we also observed strong interadenoma/intraparticipant correlation in 11 patients with multiple adenomas (Figs. 3 and 4; Supplementary Fig. S2). These results support previous findings suggesting that cancer stem cells and adenoma stem-like cells reside in a niche microenvironment (30, 45, 46). The mechanisms leading to the observed correlated deregulation of the stem cell subpopulations and their overgrowth in synchronous adenomas remain to be explained. This concept of a niche effect is consistent with previous work on the concept of field defects in carcinogenesis and supports the occurrence of a generalized intrapatient predisposition to a stem-like cell niche that participates in adenoma development.

The fraction of ALDH1A1-expressing adenoma cells was variable among subjects, with some having large fractions and others small fractions. This observation challenges the role of well-established genetic pathways such as the APC/Wnt pathway that is almost universally involved in colorectal tumorigenesis (47) in neoplastic progression of the nonadvanced tubular adenoma to the advanced adenoma via the stem-like cell subpopulation. Regulation of stem cells by several pathways in the niche has been shown, including Wnt, bone morphogenetic protein (BMP), Ets2, Notch, Twist, and Snail signaling that involve stromal-epithelial interactions (13, 25, 47–51). Furthermore, work on the genetic and epigenetic factors regulating the stem cell compartment of adenomas, and the lifestyle and exposures that influence them, may offer new opportunities for preventive intervention.

Our study has a number of strengths, including the use of two independent sample sets (an exploratory and a replication set) as well as the availability of baseline adenomas from patients from our placebo arms of trials with follow-up colonoscopy at similar intervals (average 3 years). Extensive participant- and adenoma-level characterization with central pathology review and adjudication were done and are additional strengths. We used an established immunohistochemistry method to evaluate the ALDH1A1-positive stem-like cells in their topographic tissue setting. The commercially available ALDH1A1 antibody used in this study has been extensively evaluated and shown in a previous study to identify a colorectal stem-like cell population that had the capacity to form spheroids in vitro and to successfully form tumor xenografts in vivo (40). The topographic distribution and numbers of ALDH1A1-positive stem-like cells in non-neoplastic colorectal mucosa were similar to those in previous reports (23, 34, 39). In contrast with results found with other putative stem cell markers such as CD44 and CD133 (23).

Limitations include our relatively small sample sets and the focus in the replication sample set on high-risk participants for whom adequate pathology material was available as convenience samples in the specimen repository. Furthermore, although our data are suggestive of higher ALIs in proximal adenomas, which have a higher propensity for “recurrence,” proximal adenomas commonly occur along with distal adenomas. These were often collected in the same specimen vial after polypectomy, thus limiting our ability to identify a larger, purely proximal population of adenomas.

In conclusion, our study shows for the first time that ALDH1A1 expression in a baseline adenoma is an independent risk factor for development of a metachronous adenoma. Our findings suggest that the assessment of ALDH1A1 expression is sufficiently promising to warrant further investigation as a biomarker to aid in risk assessment. Efforts in low-risk populations, where surveillance recommendations remain controversial (i.e., patients with one or two small tubular adenomas), are particularly warranted. Our observation of strong intra- and interadenoma correlation of ALDH1A1 expression at the patient level adds support to the concept of an adenoma stem cell “niche” as a putative risk site for neoplasia. Corroboration of our findings in a larger sample to obtain precise estimates of the association for clinical utility combined with mechanistic studies may offer new areas for development of colorectal cancer prevention efforts.

<table>
<thead>
<tr>
<th>Model</th>
<th>Percentage correct</th>
<th>Sensitivity</th>
<th>Specificity</th>
<th>False-positive</th>
<th>False-negative</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, gender, any advanced lesion</td>
<td>22.4</td>
<td>42.5</td>
<td>0</td>
<td>67.9</td>
<td>100</td>
</tr>
<tr>
<td>Plus ALDH1A1 (continuous)</td>
<td>56.6</td>
<td>57.5</td>
<td>55.6</td>
<td>41.0</td>
<td>45.9</td>
</tr>
<tr>
<td>Plus ALDH1A1 (median)</td>
<td>57.9</td>
<td>60.0</td>
<td>55.6</td>
<td>40.0</td>
<td>44.4</td>
</tr>
<tr>
<td>Plus ALDH1A1 (mean)</td>
<td>50.0</td>
<td>52.5</td>
<td>47.2</td>
<td>47.5</td>
<td>52.8</td>
</tr>
<tr>
<td>Plus ALDH1A1 (22.4%)</td>
<td>63.2</td>
<td>52.5</td>
<td>75.0</td>
<td>30.0</td>
<td>41.3</td>
</tr>
</tbody>
</table>

Table 3. Sensitivity and specificity of ALI and clinicopathologic risk factors for metachronous adenoma in replication set
Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.

Authors' Contributions
Conception and design: A.N. Bartley, P. Lance, C.-H. Hsu, D. J. Roe, L. Corley, P. Lance, P. Thompson, S. Hamilton
Acquisition of data (e.g., provided animals, acquired and managed patients, provided facilities, etc.): A. N. Bartley, J. A. Buckmeier, G. Gallick, P. Lance, P. Thompson, S. Hamilton
Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): A. N. Bartley, C.-H. Hsu, D. J. Roe, L. Corley, P. Lance, P. Thompson, S. Hamilton
Writing, review, and/or revision of the manuscript: A. N. Bartley, J. A. Buckmeier, G. Gallick, P. Lance, P. Thompson, S. Hamilton
Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): N. Parikh, J. A. Buckmeier, L. Corley, R. A. Thomas, P. Thompson, S. Hamilton
Study supervision: P. Lance, P. Thompson, S. Hamilton

References

Acknowledgments
The authors thank Sendurari Mani for helpful discussions and advice, Sherita Meyer-Gauen for developing the automated ALDH1A1 immunohistochemistry, and Betsy Werthem for generation of the summary data for Table 1.

Grant Support
This work was supported by the Colon Cancer Prevention Program Project Grant (National Cancer Institute NIH PO1 CA11108) and by the shared resources of The University of Texas MD Anderson Cancer Center Support Grant (P30 CA016672) and the Arizona Cancer Center Support Grant (P30 CA023074). S.R. Hamilton was supported by the Frederick F. Becker Distinguished University Chair in Cancer Research from The University of Texas.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received March 28, 2013; revised August 4, 2013; accepted August 19, 2013; published OnlineFirst September 5, 2013.